Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing gene-based treatments for cancer and diabetes. Its oncology programs use the ONCOPREX delivery system to deliver tumor suppressor genes, while its diabetes work centers on adeno-associated virus-based gene therapy licensed from the University of Pittsburgh.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSystemic, non-viral gene therapy candidates and delivery technology for cancer.
Licensed gene therapy programs targeting Type 1 and Type 2 diabetes.
Human trials and related regulatory work for lead oncology candidates.
Animal-model and IND-enabling studies supporting future product candidates.
Exclusive and non-exclusive rights from the University of Pittsburgh.
Asiakkaat
Genprex does not currently sell commercial products; its near-term counterparties are research institutions, clinical investigators, regulators, and manufacturing vendors that support development. If successful, its future customers would be oncology and diabetes patients, with commercialization likely occurring through partners or direct product sales after regulatory approval.
Universities and scientific partners that perform animal-model and translational studies to advance the pipeline.
Patients and trial centers enrolled in Acclaim-1 and Acclaim-3 to generate efficacy and safety data.
FDA and other agencies that must clear IND-enabling work and approve clinical advancement.
Specialized third parties that support process scale-up, formulation, and clinical supply.
Cancer and diabetes patients who would be treated if the company reaches approval and launch.
Strategia
Genprex is prioritizing advancement of its lead oncology trials while continuing preclinical and IND-enabling work for diabetes and other potential programs. Management is also reducing operating costs, transitioning some manufacturing activities to new vendors, and exploring strategic alternatives and financing sources to preserve liquidity and extend runway.
Clinical data are the main value driver and are needed for regulatory and partnering optionality.
The diabetes platform broadens the pipeline and could create a second development path.
The company has no product revenue and depends on external capital to fund R&D.
Gene therapy programs require reliable, scalable manufacturing to support trials and future launch.
Maantiede
Genprex is headquartered in the United States and its development work is centered there, including clinical operations, regulatory interactions, and vendor management. The company also explicitly targets regulatory approval in Europe, and its diabetes licensing arrangement is worldwide, so future value creation depends on both U.S. and international development pathways.
Riskit
Genprex is a pre-revenue biotech company with substantial clinical, regulatory, and financing risk. Its programs may fail in preclinical or clinical testing, may not obtain FDA or European approval, and may require more capital than it can raise on acceptable terms, which could force delays or program cuts.
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has recurring losses and no product sales, so it must raise capital to continue operations.
Kohdistuu - Nasdaq delisting riskVaikutus: KorkeaTodennäköisyys: Korkea
Failure to meet continued listing standards could impair liquidity and financing access.
Kohdistuu: Minimum bid price and stockholders' equity requirements
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Matala
FDA and other regulators may require additional studies or reject applications.
Kohdistuu - Clinical trial failureVaikutus: Korkea
Lead programs are still in development and may not demonstrate sufficient efficacy or safety.
Kohdistuu - Manufacturing and scale-up riskVaikutus: Keskitaso
Gene therapy production is complex and vendor transitions can affect quality and timing.
Kohdistuu: New manufacturing vendors and process adaptation
Kirjanpito
Harkinnanvaraiset erätMost development spending is expensed as incurred, directly affecting net loss and comparability across periods.
Vaikutus: Clinical, preclinical, and manufacturing costs flow through earnings immediately
Recurring losses and limited cash runway require management judgment about the ability to continue operations.
Vaikutus: Material disclosure affecting investor assessment of solvency
ATM and ELOC funding can create share issuance costs and dilution, affecting per-share metrics.
Vaikutus: Common stock outstanding and capital structure
Clinical and manufacturing programs require estimates for unpaid services and contract obligations.
Vaikutus: Expense timing and liabilities
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Greenwich LifeSciences, Inc.
GLSI · Pharmaceutical Preparations
RetinalGenix Technologies Inc.
RTGN · Surgical & Medical Instruments & Apparatus
Glucotrack, Inc.
GCTK · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026